Disruption of EGFR signaling by either genetic mutation or its kinase inhibition blocks the formation and growth of ACF, microadenomas, and adenomas as well as the growth of established tumors in ApcMin/+ and AOM-treated mice [66-68]. The gene discussed is EGFR; the disease is adenoma.